The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
HOME > April 2, 2025
Daily News
April 2, 2025
- Japan Picks 14 “Loss” Products as Drugs with Highest Priority for Development
April 2, 2025
- JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy
April 2, 2025
- Alper Alptekin Becomes Japan President of Organon
April 2, 2025
- Sumitomo Pharma to Offload Asian Biz to Trader Marubeni
April 2, 2025
- Xocova’s US Rolling Submission Starts for COVID Post-Exposure Prophylaxis
April 2, 2025
- Shoichiro Ogawa to Lead Sun Pharma Japan
April 2, 2025
- GSK’s Shingrix Buttresses Label with Long-Term Data
April 2, 2025
- MHLW Says It Will Handle Info Disclosure Requests as per Rules
April 2, 2025
- FunPep Inks Research Pact with French Public Institute on Antibody-Inducing Peptides
April 2, 2025
- Rental Lab-Style R&D Hub “iPark Kobe” to Open in KBIC
April 2, 2025
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Novartis’ Pluvicto (lutetium vipivotide tetraxetan (177Lu)) won reimbursement listing in Japan in November as a radioligand therapy (RLT) for PSMA-positive…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…